ELIXINOL WELLNESS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.004 AUD | -20.00% |
|
-20.00% | -66.67% |
| May. 13 | Elixinol Wellness Receives AU$2.3 Million from Pet Releaf Stake Sale | MT |
| Apr. 18 | Transcript : Elixinol Wellness Limited - Shareholder/Analyst Call |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 311.4 | 77.46 | 54.84 | 22.75 | 6.639 | 7.594 |
| Enterprise Value (EV) 1 | 268.7 | 61.85 | 29.75 | 12.81 | 5.679 | 8.148 |
| P/E ratio | -315 x | -0.9 x | -0.3 x | -1.33 x | -0.63 x | -0.75 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 8.39 x | 2.85 x | 3.65 x | 2.44 x | 0.94 x | 0.92 x |
| EV / Revenue | 7.24 x | 2.28 x | 1.98 x | 1.37 x | 0.8 x | 0.99 x |
| EV / EBITDA | -2,083 x | -1.95 x | -1.26 x | -0.87 x | -0.6 x | -1.38 x |
| EV / FCF | -31.2 x | -1.27 x | 3.21 x | -1.6 x | -0.98 x | -3.86 x |
| FCF Yield | -3.2% | -78.7% | 31.1% | -62.5% | -102% | -25.9% |
| Price to Book | 2.17 x | 0.7 x | 1.54 x | 1.19 x | 0.72 x | 1.18 x |
| Nbr of stocks (in thousands) | 124,550 | 137,102 | 313,360 | 315,929 | 316,132 | 632,872 |
| Reference price 2 | 2.500 | 0.5650 | 0.1750 | 0.0720 | 0.0210 | 0.0120 |
| Announcement Date | 3/27/19 | 3/30/20 | 2/25/21 | 2/25/22 | 2/27/23 | 3/11/24 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 37.13 | 27.18 | 15.01 | 9.338 | 7.055 | 8.269 |
| EBITDA 1 | -0.129 | -31.67 | -23.58 | -14.68 | -9.482 | -5.921 |
| EBIT 1 | -0.953 | -33.24 | -25.33 | -15.17 | -9.75 | -6.044 |
| Operating Margin | -2.57% | -122.29% | -168.73% | -162.48% | -138.2% | -73.09% |
| Earnings before Tax (EBT) 1 | -0.497 | -73.62 | -100.3 | -17.09 | -10.57 | -7.504 |
| Net income 1 | -0.86 | -82.93 | -104.5 | -17.02 | -10.57 | -7.507 |
| Net margin | -2.32% | -305.07% | -696.24% | -182.32% | -149.84% | -90.78% |
| EPS 2 | -0.007948 | -0.6271 | -0.5825 | -0.0541 | -0.0334 | -0.0159 |
| Free Cash Flow 1 | -8.605 | -48.67 | 9.26 | -8.011 | -5.814 | -2.11 |
| FCF margin | -23.17% | -179.06% | 61.69% | -85.79% | -82.41% | -25.51% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/27/19 | 3/30/20 | 2/25/21 | 2/25/22 | 2/27/23 | 3/11/24 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 0.55 |
| Net Cash position 1 | 42.7 | 15.6 | 25.1 | 9.93 | 0.96 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.0936 x |
| Free Cash Flow 1 | -8.6 | -48.7 | 9.26 | -8.01 | -5.81 | -2.11 |
| ROE (net income / shareholders' equity) | -0.71% | -51.7% | -142% | -62.2% | -74.9% | -96.1% |
| ROA (Net income/ Total Assets) | -0.46% | -15.1% | -19.4% | -28% | -31.4% | -30% |
| Assets 1 | 186.8 | 549.8 | 539.8 | 60.87 | 33.67 | 25.04 |
| Book Value Per Share 2 | 1.150 | 0.8100 | 0.1100 | 0.0600 | 0.0300 | 0.0100 |
| Cash Flow per Share 2 | 0.3400 | 0.1500 | 0.0900 | 0.0400 | 0.0100 | 0 |
| Capex 1 | 4.73 | 9.94 | 0.3 | 0.16 | 0.01 | 0.01 |
| Capex / Sales | 12.75% | 36.58% | 1.97% | 1.71% | 0.07% | 0.15% |
| Announcement Date | 3/27/19 | 3/30/20 | 2/25/21 | 2/25/22 | 2/27/23 | 3/11/24 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -66.67% | 4.35M | |
| +33.83% | 107B | |
| -5.15% | 39.31B | |
| +24.55% | 34.56B | |
| +16.04% | 33.02B | |
| +25.61% | 21.41B | |
| +21.27% | 19.84B | |
| -1.78% | 8.92B | |
| +8.81% | 8.43B | |
| +10.76% | 6.96B |
- Stock Market
- Equities
- EXL Stock
- Financials Elixinol Wellness Limited